Incannex Healthcare Inc
IXHL
Company Profile
Business description
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.
Contact
8 Century Circuit Norwest
Suite 105
SydneyNSW3000
AUST: +61 409840786
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
30 June 2026
Employees
9
Stocks News & Analysis
stocks
Ask the analyst: Are markets missing something with CSL?
I catch up with Shane Ponraj after an eventful reporting season for healthcare major CSL.
stocks
This ASX stock’s bubble has well and truly burst
Pandemic related tailwinds are a distant memory for Reece, which looks set to face more competition in Australia.
stocks
Tesla’s stock is in trouble, but this fund manager sees a comeback in 2026
Tesla’s challenges echo past issues the company has overcome, says Zevenbergen’s Joe Dennison.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,231.10 | 2.60 | 0.03% |
| CAC 40 | 7,743.93 | 34.12 | 0.44% |
| DAX 40 | 24,046.21 | 106.66 | -0.44% |
| Dow JONES (US) | 45,565.23 | 147.16 | 0.32% |
| FTSE 100 | 9,255.50 | 10.30 | -0.11% |
| HKSE | 25,201.76 | 323.16 | -1.27% |
| NASDAQ | 21,590.14 | 45.87 | 0.21% |
| Nikkei 225 | 42,520.27 | 125.87 | 0.30% |
| NZX 50 Index | 12,861.84 | 96.14 | -0.74% |
| S&P 500 | 6,481.40 | 15.46 | 0.24% |
| S&P/ASX 200 | 8,960.50 | 0.70 | -0.01% |
| SSE Composite Index | 3,800.35 | 68.03 | -1.76% |